Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to attend LIVE "Market on Close" program each Friday with John Rowland. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Novartis Ag ADR (NVS)

Novartis Ag ADR (NVS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Cancer Research Sees Major Boost as New Breakthroughs Emerge from Key Oncology Players

/CNW/ -- USA News Group – In the oncology world, there's been plenty to celebrate recently, with cancer deaths falling by 33% in the last 30 years. However,...

ONCY : 0.9500 (+2.15%)
NVS : 116.21 (+0.21%)
LNTH : 109.24 (+1.02%)
STRO : 4.06 (+2.78%)
ZYME : 12.83 (+2.48%)
ONC.TO : 1.30 (+1.56%)
Recent Breakthroughs in Cancer Research Could Impact These Key Companies

Issued on behalf of Oncolytics Biotech Inc. VANCOUVER – USA News Group – In the oncology world, there’s...

ONCY : 0.9500 (+2.15%)
ONC.TO : 1.30 (+1.56%)
NVS : 116.21 (+0.21%)
LNTH : 109.24 (+1.02%)
STRO : 4.06 (+2.78%)
ZYME : 12.83 (+2.48%)
Novartis Wins FDA Approval of Kisqali for Early Breast Cancer

Novartis NVS announced that the FDA has approved breast cancer drug Kisqali (ribociclib) for a broader population.The regulatory body approved Kisqali in combination with an aromatase inhibitor (AI) for...

NVS : 116.21 (+0.21%)
PFE : 29.73 (-0.07%)
LLY : 910.65 (+0.63%)
Novartis' Kisqali Lowers Risk of Breast Cancer Recurrence by 28%

Novartis NVS announced positive data on breast cancer drug Kisqali (ribociclib) from the late-stage study, NATALEE.This late-breaking data from this four-year post-hoc analysis was presented at the European...

NVS : 116.21 (+0.21%)
PFE : 29.73 (-0.07%)
LLY : 910.65 (+0.63%)
BAYRY : 8.1000 (+3.98%)
Lilly Gets FDA Approval for Eczema Drug Ebglyss

Eli Lilly and Company LLY announced that the FDA has granted approval to its IL-13 inhibitor Ebglyss (lebrikizumab) for treating moderate-to-severe atopic dermatitis, also called eczema. Ebglyss is approved...

NVS : 116.21 (+0.21%)
BIIB : 203.54 (+3.01%)
PFE : 29.73 (-0.07%)
LLY : 910.65 (+0.63%)
Roche Gets FDA Approval for Subcutaneous Formulation of Tecentriq

Roche RHHBY announced that the FDA has approved the subcutaneous (SC) formulation of the blockbuster immunotherapy drug Tecentriq (atezolizumab).The SC formulation was approved under the brand name Tecentriq...

NVS : 116.21 (+0.21%)
RHHBY : 39.4500 (-0.40%)
LLY : 910.65 (+0.63%)
Boost Your Portfolio's Health With These 4 Large-Cap Drug Stocks

Large drug-maker stocks have witnessed a strong run this year, driven by positive pipeline news and regulatory approvals. The FDA has granted approval to 29 novel drugs this year. Innovation in the industry...

NVS : 116.21 (+0.21%)
RHHBY : 39.4500 (-0.40%)
PFE : 29.73 (-0.07%)
LLY : 910.65 (+0.63%)
Sanofi, Regeneron's Dupixent Meets Late-Stage Urticaria Study Goals

Sanofi SNY and Regeneron REGN announced encouraging data from the confirmatory phase III LIBERTY-CUPID C study evaluating their blockbuster drug Dupixent (dupilumab) in chronicspontaneous urticaria (CSU)...

REGN : 1,159.87 (+1.85%)
SNY : 58.04 (+0.99%)
NVS : 116.21 (+0.21%)
RHHBY : 39.4500 (-0.40%)
Junior Biotech Utilizes AI To Shorten Drug Discovery Timelines, Ultimately Saving Lives

The urgent need for innovative technologies to accelerate the development of life-saving %Cancer therapies has never been more critical. With millions of lives and billions of dollars at stake, the potential...

MRK : 116.93 (-1.44%)
NVS : 116.21 (+0.21%)
KTRA : 0.1808 (+3.31%)
RKV.VN : 0.085 (unch)
RHHBY : 39.4500 (-0.40%)
XBIT : 7.74 (+3.20%)
BMRN : 71.88 (+1.04%)
AZN : 79.21 (+0.80%)
Bayer Reports Encouraging NSCLC Drug Data, Gets Approval for Eylea 8mg

Bayer BAYRY announced positive results from the expansion part of the ongoing early to mid-stage study on pipeline candidate BAY 2927088.BAY 2927088 is an oral, reversible tyrosine kinase inhibitor (TKI)...

REGN : 1,159.87 (+1.85%)
NVS : 116.21 (+0.21%)
LLY : 910.65 (+0.63%)
BAYRY : 8.1000 (+3.98%)

Barchart Exclusives

Will the Tesla Robotaxi Reveal Be a Sell-the-News Event?
With EV giant Tesla on the brink of launching its game-changing Robotaxi next month, what stance should investors adopt ahead of this major event? Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar